{
  "id": 2874,
  "text": "Changgeng Yi Xue Za Zhi 21, 291-299 (1998).729.Curtin, J.P., et al.Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Changgeng Yi Xue Za Zhi 21, 291-299 (1998).729.Curtin, J.P., et al.Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据现有研究中的比较结果，对于接受根治性子宫切除术和盆腔淋巴结清扫术的高危宫颈癌患者，辅助化疗与化疗联合盆腔放疗在效果上存在一定差异。化疗联合盆腔放疗通常被认为能更有效地降低局部复发风险，并可能在一定程度上改善患者的无病生存率（DFS）和总体生存率（OS），尤其是对于存在盆腔淋巴结转移或切缘阳性的患者而言。相较之下，单独辅助化疗可能不足以提供同等的局部控制能力。\n\n然而，治疗选择需综合考虑患者的具体病理特征（如分期、组织学类型、手术切缘状态、淋巴结转移情况等）以及个体耐受性、副作用和生活质量评估。因此，在治疗方案的决定上，建议患者与肿瘤治疗团队密切沟通，进行个性化处理。",
  "query": "根据提供的 <text>，它确实涉及宫颈癌相关内容，因此问题如下：\n\n**宫颈癌高危患者在根治性子宫切除术和盆腔淋巴结清扫术后，辅助化疗与化疗联合盆腔放疗的效果差异如何？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据提供的 <text>，它确实涉及宫颈癌相关内容，因此问题如下：\n\n**宫颈癌高危患者在根治性子宫切除术和盆腔淋巴结清扫术后，辅助化疗与化疗联合盆腔放疗的效果差异如何？**\n\n<reference text>: Changgeng Yi Xue Za Zhi 21, 291-299 (1998).729.Curtin, J.P., et al.Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据现有研究中的比较结果，对于接受根治性子宫切除术和盆腔淋巴结清扫术的高危宫颈癌患者，辅助化疗与化疗联合盆腔放疗在效果上存在一定差异。化疗联合盆腔放疗通常被认为能更有效地降低局部复发风险，并可能在一定程度上改善患者的无病生存率（DFS）和总体生存率（OS），尤其是对于存在盆腔淋巴结转移或切缘阳性的患者而言。相较之下，单独辅助化疗可能不足以提供同等的局部控制能力。\n\n然而，治疗选择需综合考虑患者的具体病理特征（如分期、组织学类型、手术切缘状态、淋巴结转移情况等）以及个体耐受性、副作用和生活质量评估。因此，在治疗方案的决定上，建议患者与肿瘤治疗团队密切沟通，进行个性化处理。"
}